MEDICAL ADVOCATES
WOMEN AND HIV RESOURCE CENTER
  ARV/HAART Pregnancy Studies
 		  
General Studies
 Treatment Guidelines
Safety and Efficacy
Virological Response
Tolerability   
Resistance
Therapeutic Drug Monitoring
Immune Status
 Adverse Events
 Outcome Studies
Adherence		 Treatment Interruption
Discontinuation of ARVs
ARVs and Vaginal Delivery
ARVs and C-Sections
ARVs and Vaginal Delivery
ARVs and Breast Milk
Protease Inhibitors
Nucleoside Analogues  
NNRTIs 
Treatment of Neonates
 


 
HIV Pregnancy Main Page Women Main Page  
Last Update:  February 28, 2015
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Studies/Reports
 
           Journal Papers, Abstracts, and Commentaries
 
 
Prevention of mother-to-child transmission of HIV Type 1: the role of neonatal and infant prophylaxis.
 Hurst SA, Appelgren KE, Kourtis AP.
Expert Rev Anti Infect Ther. 2015 Feb;13(2):169-81.
 Abstract

FULL-TEXT ARTICLE
 A Systematic Review of Health System Barriers and Enablers for Antiretroviral Therapy (ART) for HIV-Infected Pregnant and Postpartum Women.
 Colvin CJ, Konopka S, Chalker JC, et al
PLoS One. 2014 Oct 10;9(10):e108150
 Paper

Benefit of Inter-Pregnancy Hiv Viral Load Suppression on Subsequent Maternal and Infant Outcomes.
 Stewart RD, Wells CE, Roberts SW, et al
Am J Obstet Gynecol. 2014 Apr 15.
 Abstract

Pharmacologic prevention of perinatal HIV infection.
Rakhmanina NY, van den Anker JN.
 Early Hum Dev. 2014 Mar;90S1:S13-S15.
Abstract

Risk factors of hiv-1 vertical transmission (vt) and the influence of antiretroviral therapy (art) in pregnancy outcome.
Barral MF, Oliveira GR, Lobato RC,  et al
Rev Inst Med Trop Sao Paulo. 2014 Mar-Apr;56(2):133-8.
 Abstract

Antiretroviral therapy and preterm birth in HIV-infected women.
Short CE, Taylor GP. Expert Rev A
nti Infect Ther. 2014 Feb 6.
 Abstract

The impact of maternal anti-retroviral therapy on cytokine profile in the uninfected neonates.
 Kasahara TM, Hygino J, Blanco B,et al
Hum Immunol. 2013 Jun 17.
 Abstract

Antiretroviral Drugs to Prevent Mother-to-Child Transmission of HIV during Breastfeeding.
 Shetty AK, Maldonado Y.
Curr HIV Res. 2013 Feb 21
 Abstract

Combination Antiretroviral Use and Preterm Birth.
 Watts DH, Williams PL, Kacanek D, et al 
J Infect Dis. 2012 Nov 29
 Abstract

Pregnancy and treatment interruption enhances progression of HIV-infection if initial CD4(+) T-lymphocyte count is less than 700 cells/mm(3).
Orlova-Morozova E, Pronin A, Kaminskiy G.
 J Int AIDS Soc. 2012 Nov 11;15(6):
 Abstract

Pharmacokinetic optimization of antiretroviral therapy in pregnancy.
 Buckoreelall K, Cressey TR, King JR.
Clin Pharmacokinet. 2012 Oct;51(10):639-59.
 Abstract

FULL-TEXT ARTICLE
 Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.
 Nielsen-Saines K, Watts DH, Veloso VG   et al
N Engl J Med. 2012 Jun 21;366(25):2368-7
 Paper

Leukocyte Telomere Length in HIV-Infected Pregnant Women Treated with Antiretroviral Drugs During
Pregnancy and Their Uninfected Infants.
Imam T, Jitratkosol MH, Soudeyns H,  et al
J Acquir Immune Defic Syndr. 2012 May 10.
 Abstract

Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up
of the BAN randomised controlled trial.
 Jamieson DJ, Chasela CS, Hudgens MG,  et al
Lancet. 2012 Apr 25.
Abstract

A Trigger-based Design for Evaluating the Safety of In Utero Antiretroviral Exposure in Uninfected Children of Human Immunodeficiency Virus-Infected Mothers.
 Williams PL, Seage GR 3rd, Van Dyke RB,  et al
Am J Epidemiol. 2012 Apr
Abstract

Pharmacokinetic Considerations of Perinatal Antiretroviral Therapy.
 Rakhmanina NY, Dirajlal-Fargo S, Capparelli EV, Mirochnik M.
Curr Drug Metab. 2012 Mar 22.
 Abstract

When should HAART be initiated in pregnancy to achieve an undetectable HIV viral load by delivery?
 Read PJ, Mandalia S, Khan P,  et al
AIDS. 2012 Mar 21.
Abstract

Short- and Long-term Immunological and Virological Outcome in HIV-Infected Infants
According to the Age at Antiretroviral Treatment Initiation.
Goetghebuer T, Le Chenadec J, Haelterman E,  et al
Clin Infect Dis. 2011 Dec 23.
 Abstract

Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment
(placenta and amniotic fluid).
 Else LJ, Taylor S, Back DJ, Khoo SH.
 Antivir Ther. 2011;16(8):1139-47.
 Abstract

Current Treatment Strategies, Complications and Considerations for the Use of HIV
Antiretroviral Therapy during Pregnancy.
Senise JF, Castelo A, Martínez M.
 AIDS Rev. 2011 Oct;13(4):198-213.|
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Timing of Antiretroviral Therapy Initiation and its Impact on Disease Progression in Perinatal Human Immunodeficiency
Virus- Infection.
 Sturt AS, Halpern MS, Sullivan B, Maldonado YA.
Pediatr Infect Dis J. 2011 Oct 5.
 Abstract

Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
 Siegfried N, van der Merwe L, Brocklehurst P, Sint TT.
Cochrane Database Syst Rev. 2011 Jul 6;(7):CD003510
 Abstract

Optimal Time on HAART for Prevention of Mother-to-Child Transmission of HIV.
 Chibwesha CJ, Giganti MJ, Putta N, et al
J Acquir Immune Defic Syndr. 2011 Jun 24
 Abstract

Antiretroviral use during pregnancy for treatment or prophylaxis.
 Sturt AS, Read JS.
Expert Opin Pharmacother. 2011 May 3
 Abstract

Mother-to-child transmission of HIV-1 in the era prior to the availability of combination antiretroviral therapy:
The role of drugs of abuse.
 Van Dyke RB.
Life Sci. 2011 Mar 30.
 Abstract

Antiretroviral Drugs in the Cupboard Are Not Enough: The Impact of Health Systems' Performance on
Mother-to-Child Transmission of HIV.
 Barker PM, Mphatswe W, Rollins N.
J Acquir Immune Defic Syndr. 2010 Nov 16
 Abstract

Maternal or Infant Antiretroviral Drugs to Reduce HIV-1 Transmission.
[No authors listed]
N Engl J Med. 2010 Nov 11;363(20):1968-70.
 Abstract
 
Maternal or Infant Antiretroviral Drugs to Reduce HIV-1 Transmission.
 Tattevin P, Arvieux C, Courpotin C.
N Engl J Med. 2010 Nov 11;363(20):1968-70
 Abstract
 
Maternal or Infant Antiretroviral Drugs to Reduce HIV-1 Transmission.
 Ekouevi DK.
N Engl J Med. 2010 Nov 11;363(20):1968-70.
 Abstract
 
Maternal or Infant Antiretroviral Drugs to Reduce HIV-1 Transmission.
 Bell DM, Brewinski MM, Holmes CB.
N Engl J Med. 2010 Nov 11;363(20):1968-70.
 Abstract

Antiretroviral therapy and preterm delivery-a pooled analysis of data from the United States
and Europe.
 Townsend C, Schulte J, Thorne C,  et al
BJOG. 2010 Aug 17
 Abstract

Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.
 Chasela CS, Hudgens MG, Jamieson DJ, et al
N Engl J Med. 2010 Jun 17;362(24):2271-81.
 Abstract

Postpartum Plasma CD4 Change in HIV-Positive Women: Implications for
Timing of HAART Initiation.
Koyanagi A, Ruff AJ, Moulton LH, et al
AIDS Res Hum Retroviruses. 2010 May 10
 Abstract

Antiretroviral therapy and bone mineral measurements in HIV-infected youths.
 Zuccotti G, Viganň A, Gabiano C,  et al 
Bone. 2010 Mar 5.
 Abstract

Use of antiretrovirals during pregnancy and breastfeeding in low-income and middle-income countries.
 McIntyre J.
Curr Opin HIV AIDS. 2010 Jan;5(1):48-53.
 Abstract

Initiation of antiretroviral therapy among pregnant women in resource-limited countries:
CD4+ cell count response and program retention.
 Toro PL, Katyal M, Carter RJ, et al
AIDS. 2009 Dec 7
 Abstract

Transplacental Transfer of Antiretroviral Drugs and Newborn Birth Weight in HIV-Infected Pregnant Women.
Ivanovic J, Nicastri E, Anceschi MM, et al
Curr HIV Res. 2009 Nov;7(6):620-5.
 Abstract

Antiretroviral therapy in antenatal care to increase treatment initiation in HIV-infected pregnant women: a stepped-wedge evaluation.
 Killam WP, Tambatamba BC, Chintu N, et al 
AIDS. 2009 Oct 3
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
FULL-TEXT ARTICLE
 Antiretroviral therapy initiation before, during, or after pregnancy in HIV-1-infected women:
maternal virologic, immunologic, and clinical response.
 Melekhin VV, Shepherd BE, Stinnette SE, et al
PLoS One. 2009 Sep 9;4(9):e6961.
 Paper

Influence of highly active antiretroviral treatment (HAART) on risk factors for vertical
HIV transmission.
Garcia-Tejedor A, Maiques V, Perales A, Lopez-Aldeguer J.
 Acta Obstet Gynecol Scand. 2009 Jun 24:1-6.
 Abstract

Antiretroviral Treatment in Pregnancy: A Six-Year Perspective on Recent Trends in
Prescription Patterns, Viral Load Suppression, and Pregnancy Outcomes.
 Baroncelli S, Tamburrini E, Ravizza M, et al
 AIDS Patient Care STDS. 2009 Jun 16
Abstract

In utero exposure to antiretroviral therapy: feasibility of long-term follow-up.
 Hankin C, Lyall H, Willey B, et al
AIDS Care. 2009 Jun 5:1-8.
Abstract

Antiretroviral Medications During Pregnancy for Therapy or Prophylaxis.
 Stek AM.
Curr HIV/AIDS Rep. 2009 May;6(2):68-76.
 Abstract

Prophylactic antiretroviral regimens for prevention of mother-to-child transmission of HIV in
resource-limited settings.
Arrivé E, Dabis F.
 Curr Opin HIV AIDS. 2008 Mar;3(2):161-5
 Abstract
 
Vaccines for prevention of mother-to-child transmission of HIV.
Cunningham CK, McFarland E.
 Curr Opin HIV AIDS. 2008 Mar;3(2):151-4
 Abstract
 
Antiretroviral treatment in pregnancy.
Stek AM. 
Curr Opin HIV AIDS. 2008 Mar;3(2):155-60.
 Abstract

Genital Tract, Cord Blood, and Amniotic Fluid Exposures of Seven Antiretroviral Drugs During and
After Pregnancy in HIV-1 Infected Women.
 Yeh RF, Rezk NL, Kashuba AD, et al 
Antimicrob Agents Chemother. 2009 Mar 23.
Abstract
 
Role of placental ATP-binding cassette (ABC) transporters in antiretroviral therapy during pregnancy.
Gulati A, Gerk PM. J
Pharm Sci. 2008 Dec 9.
 Abstract
 
IL-10-secreting T cells from HIV-infected pregnant women downregulate HIV-1 replication: effect enhanced by
antiretroviral treatment.
 Bento CA, Hygino J, Andrade RM,  et al
AIDS. 2009 Jan 2;23(1):9-18.
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Pregnancy outcome in HIV-1 infected women receiving combination antiretroviral therapy prior
versus after conception.
Machado ES, Hofer CB, Costa TT, et al 
Sex Transm Infect. 2008 Nov 5
 Abstract
 
Antiretroviral treatment during pregnancy.
Keiser O, Gayet-Ageron A, Rudin C, Brinkhof MW, et al  
AIDS. 2008 Nov 12;22(17):2323-30
 Abstract
 
Increased mtDNA Levels Without Change in Mitochondrial Enzymes in Peripheral Blood Mononuclear
Cells of Infants Born to HIV-Infected Mothers on Antiretroviral Therapy.
 McComsey GA, Kang M, Ross AC, et al
HIV Clin Trials. 2008 Jan 1;9(2):126-136.
 Abstract

Immunologic features of HIV-1-infected women on HAART at delivery.
Ono E, Dos Santos AM, Machado DM, et al
Cytometry B Clin Cytom. 2008 Apr 7 ||
 Abstract
 
Effects of antiretroviral agents during pregnancy on liver enzymes and amylase in
HIV-exposed, uninfected newborn infants.
El Beitune P, Duarte G, Campbell O, et al
Braz J Infect Dis. 2007 Jun;11(3):314-7.
 Abstract
 
ARTICLE
Characteristics and management of HIV-1-infected pregnant women enrolled in a
randomised trial: differences between Europe and the USA.
Newell ML, Huang S, Fiore S, et al   
BMC Infect Dis. 2007 Jun 20;7(1):60
 Paper
 
A WEEK-IN-REVIEW FEATURED REPORT
Time to undetectable viral load after highly active antiretroviral therapy initiation among
HIV-infected pregnant women.
European Collaborative Study; Patel D, Cortina-Borja M, Thorne C, Newell ML.
Clin Infect Dis. 2007 Jun 15;44(12):1647-56.
 Abstract
 
AIDS in pregnancy, part II: Treatment in the era of highly active antiretroviral therapy
and management of obstetric, anesthetic, and pediatric issues.
Rigopoulos D, Gregoriou S, Paparizos V, Katsambas A.
Skinmed. 2007 Mar-Apr;6(2):79-84
 Abstract
 
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
Volmink J, Siegfried N, van der Merwe L, Brocklehurst P.
Cochrane Database Syst Rev. 2007 Jan 24;(1):CD003510.
 Abstract
 
A Prospective Controlled Study of Neurodevelopment in HIV-Uninfected Children Exposed to
Combination Antiretroviral Drugs in Pregnancy.
Alimenti A, Forbes JC, Oberlander TF, et al
Pediatrics. 2006 Aug 28;
 Abstract
 
Longitudinal Relationships Between Use of Highly Active Antiretroviral Therapy and
Satisfaction With CareAmong Women Living With HIV/AIDS.
Burke-Miller JK, Cook JA, Cohen MH, et al
Am J Public Health. 2006 May 2;
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Failure to eradicate HIV despite fully successful HAART initiated in the first days of life.
Vigano A, Trabattoni D, Schneider L,
Pediatr. 2006 Mar;148(3):389-91.
Abstract

Highly Active Antiretroviral Therapy Started during Pregnancy or Postpartum Suppresses
HIV-1 RNA, but Not DNA, in Breast Milk.
 Shapiro RL, Ndung'u T, Lockman S, et al  Infect Dis. 2005 Sep 1;192(5):713-9.
Abstract
 
Effect of antiretroviral agents on carbohydrate metabolism in HIV-1 infected pregnant women.
 Beitune PE, Duarte G, Foss MC, Montenegro RM Jr, et al 
Diabetes Metab Res Rev. 2005 Jul 15; 
Abstract 
 
Antiretroviral therapy and pregnancy
Wunder D, Evison JM.   
Ther Umsch. 2005 Jan;62(1):37-42
 Abstract 
 
Mother-to-Child Transmission of HIV Infection in the Era of Highly Active
Antiretroviral  Therapy.
European Collaborative Study.
Clin Infect Dis. 2005 Feb 1;40(3):458-465
 Abstract 
 
Decrease in Hospitalization and Mortality Rates among Children with Perinatally
Acquired HIV Type 1 Infection Receiving Highly Active Antiretroviral Therapy.
Viani RM, Araneta MR, Deville JG, Spector SA. et al
Clin Infect Dis. 2004 Sep 1;39(5):725-31.
 Abstract 

FULL-TEXT ARTICLE
 Women's reasons for not participating in follow up visits before starting short
course antiretroviral prophylaxis for prevention of mother to child transmission
of HIV: qualitative interview study
Painter TM, Diaby KL, Matia DM, et al 
BMJ  2004;329:543
 Paper

Use of antiretroviral drugs to prevent HIV-1 transmission through breast-feeding:
from animal studies to randomized clinical trials.
Gaillard P, Fowler MG, Dabis F, et al   
J Acquir Immune Defic Syndr. 2004 Feb 1;35(2):178-87.
 Abstract 

Immunoprophylaxis to prevent mother-to-child transmission of HIV-1.
 Safrit JT, Ruprecht R, Ferrantelli F, et al   
J Acquir Immune Defic Syndr. 2004 Feb 1;35(2):169-77.
Abstract
 
Decision analysis to guide choice of interventions to reduce mother-to-child
transmission of HIV.
Bertolli J, Hu DJ, Nieburg P, et al.
AIDS. 2003 Sep 26;17(14):2089-98.
 Abstract
 
Human immunodeficiency virus and pregnancy.
 Kotler DP.
 Gastroenterol Clin North Am 2003 Mar;32(1):437-48,
Abstract
 
Antiretroviral therapy in HIV-infected pregnant women and their infants: current
interventions and challenges.
 Shannon M.
J Perinat Neonatal Nurs 2002 Sep;16(2):1-25
Abstract
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV
infection (Cochrane Review).
 Brocklehurst P, Volmink J.  
 Cochrane Database Syst Rev 2002;(1):CD003510
Abstract
 
          Conference Reports, Abstracts, and Posters
 
 

Impact of HAART on reducing mortality of HIV+ pregnant women (PW) with advanced
HIV disease in the setting of PMTCT
 Deschamps MM, Bonhomme J, Marcelin A,  et al
 (4th IAS Conference)
 Abstract
Safety and Efficacy
 
          Journal Papers, Abstracts, and Commentaries
 
 
A WEEK-IN-REVIEW FEATURED REPORT
FULL-TEXT ARTICLE
 Safety and Tolerability of Antiretrovirals during Pregnancy.
 Weinberg A, Forster-Harwood J, Davies J, et al
Infect Dis Obstet Gynecol. 2011;2011:867674.
Paper

The safety of highly active antiretroviral therapy for the HIV-positive pregnant mother and her baby:
is 'the more the merrier'?
 Martin F, Taylor GP. 
J Antimicrob Chemother. 2009 Aug 25.
Abstract

No relation between in-utero exposure to HAART and intrauterine growth retardation.
 Briand N, Mandelbrot L, Le Chenadec J, et al 
AIDS. 2009 May 6
 Abstract

Effect of antiretroviral drugs on maternal CD4 lymphocyte counts, HIV-1 RNA levels,
 and anthropometric parameters of their neonates.
 El Beitune P, Duarte G, Machado AA, et al 
Clinics. 2005 Jun;60(3):207-212.
Abstract
 
The safety of antiretroviral drugs in pregnancy.
Thorne C, Newell ML.
Expert Opin Drug Saf. 2005 Mar;4(2):323-35. R
 Abstract

Simplified antiviral prophylaxis with or and without artificial feeding to reduce
mother-to-child transmission of HIV in low and middle income countries:
modelling positive and negative impact on child survival.
Walley J, Witter S, Nicoll A.
Med Sci Monit 2001 Sep;7(5):1043-1051
 Abstract

Antiretroviral therapy in pregnancy: a focus on safety.
Taylor GP, Low-Beer
N.Drug Saf 2001;24(9):683-702
 Abstract

The efficacy and tolerability of combination antiretroviral therapy in pregnancy:
infant andmaternal outcome.
Clarke SM, Mulcahy F, Healy CM, Condon S, Butler K.
Int J STD AIDS 2000 Apr;11(4):220-3
Abstract

Antiretroviral therapies in pregnancy: maternal, fetal and neonatal  effects.
Swiss HIV CohortStudy, the Swiss Collaborative HIV and Pregnancy Study,
and the Swiss Neonatal HIV Study. 
Lorenzi P, Spicher VM, Laubereau B, Hirschel B, et al.
AIDS 1998 Dec 24;12(18):F241-7 
Abstract

 		 
          Conference Reports, Abstracts, and Posters
 
 
Highly active antiretroviral therapy (HAART) in pregnant HIV-infected women.
Efficacy and safety for the mothers and infants
B Vandercam, M Dupont, F Abarzua
(15IAC)
 Abstract
 
Optimal HAART in pregnant women with multi-drug resistant virus
J Gilmore, J R Kostman
 (15IAC)
 Abstract
 
ANTIRETROVIRAL TREATMENT IN HIV-INFECTED PREGNANT WOMEN:
EFFICACY, SAFETY AND IMPACT ON DURATION OF PREGNANCY
A. Maccabruni, G. Bossi, M.F. Ravagni Probizer, A. Moretti
 (2nd IAS)
 Abstract
 
Tolerability
 
          Journal Papers, Abstracts, and Commentaries
 
  The efficacy and tolerability of combination antiretroviral therapy in pregnancy
infant and maternal outcome
Clarke SM, Mulcahy F, Healy CM, Condon S, Butler KM
Int J STD AIDS 2000
Abstract
Immune Status
 
          Journal Papers, Abstracts, and Commentaries
 
  Immune Status and Uptake of Antiretroviral Interventions to Prevent
Mother-to-Child Transmission of HIV-1 in Africa.
For the ANRS 1201/1202 Ditrame Plus Study Group.
J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):755-757.
 Abstract
Virological Response
 
          Journal Papers, Abstracts, and Commentaries
 
  Factors Associated With Lack of Viral Suppression at Delivery Among Highly Active Antiretroviral Therapy-Naive Women With HIV: A Cohort Study.
Katz IT, Leister E, Kacanek D,  et al
Ann Intern Med. 2015 Jan 20;
 Abstract

FULL-TEXT ARTICLE
Virological profile of pregnant HIV positive women with high levels of CD4 count in low income settings:
Can viral load help as eligibility criteria for maternal triple ARV prophylaxis (WHO 2010 option B)?
Njom Nlend AE, Same Ekobo C, Moyo ST, et al
 Pan Afr Med J. 2011;10:27.
Paper

Factors associated with virological response in women receiving highly-active antiretroviral prophylaxis
for HIV-1 mother-to-child transmission.
 Palacios R, Senise JF, Vaz MJ, Castelo A. 
Enferm Infecc Microbiol Clin. 2008 Aug-Sep;26(7):411-5.
 Abstract
Resistance
 
            Journal Papers, Abstracts, and Commentaries 
                       
 
Next generation sequencing improves detection of drug resistance mutations in infants after PMTCT failure.
Fisher RG, Smith DM, Murrell B,  et al
J Clin Virol. 2015 Jan;62:48-53.
Abstract

HIV Drug Resistance in Mothers and Infants Following Use of Antiretrovirals to Prevent Mother-to-Child-Transmission.
 Ton Q, Frenkel L.
 Curr HIV Res. 2013 Feb 21
 Abstract

Impact of Maternal and Infant Antiretroviral Drug Regimens on Drug Resistance in HIV-Infected Breastfeeding Infants.
Fogel JM, Mwatha A, Richardson P, et al
Pediatr Infect Dis J. 2012 Dec 17.|
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
 HIV drug resistance and mother-to-child transmission of HIV.
 Weidle PJ, Nesheim S.
Clin Perinatol. 2010 Dec;37(4):825-42
 Abstract

Resistance considerations in sequencing of antiretroviral therapy in low-middle income countries
with currently available options.
 De Luca A, Prosperi M, Bracciale L.
Curr Opin HIV AIDS. 2010 Jan;5(1):27-37
 Abstract

Lower Risk of Resistance After Short-Course HAART Compared With Zidovudine/Single-Dose Nevirapine
Used for Prevention of HIV-1 Mother-to-Child Transmission.
Lehman DA, Chung MH, Mabuka JM, et a
 J Acquir Immune Defic Syndr. 2009 Jun 4
 Abstract

Time Trends for HIV-1 Antiretroviral Resistance Among Antiretroviral-Experienced and -Naive
Pregnant Women in New York City During 1991 to Early 2001.
Welles SL, Bauer GR, Larussa PS, et al
J Acquir Immune Defic Syndr. 2006 Dec 14
 Abstract
 
Emergence of antiretroviral resistance in HIV-positive women receiving
combination antiretroviral therapy in pregnancy.
Lyons FE, Coughlan S, Byrne CM, et al
AIDS. 2005 Jan 3;19(1):63-67.
 Abstract

Mother-to-child transmission of drug-resistant HIV. 
Kijak GH, Avila MM, Salomon H.
 Drug Resist Updat 2001 Feb;4(1):29-37
 Abstract
The role of antiretrovirals and drug resistance in vertical transmission of
HIV-1 infection.
Brenner BG, Wainberg MA
Ann N Y Acad Sci 2000 Nov;918:9-15 
Abstract

  

          Conference Reports, Abstracts, and Posters

 
Different development of HIV drug resistance mutation patterns in Subtype 06_cpx after
mother-to-child transmission
 M Stürmer, A Carlebach, S Staszewski
 (8th Int Congress on Drug Therapy in HIV Infection)
 Abstract 


Abstract

  
Therapeutic Drug Monitoring
 
          Journal Papers, Abstracts, and Commentaries
 
  Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women.
 Roustit M, Jlaiel M, Leclercq P, Stanke-Labesque F.
Br J Clin Pharmacol. 2008 Jun 4.
 Abstract
Outcome Studies
 
            Journal Papers, Abstracts, and Commentaries 
 
 
FULL-TEXT ARTICLE
 Pregnancy and Infant Outcomes among HIV-Infected Women Taking Long-Term ART
with and without Tenofovir in the DART Trial.
 Gibb DM, Kizito H, Russell EC,  et al
PLoS Med. 2012 May;9(5):e1001217
 Paper

Obstetric and newborn infant outcomes in human immunodeficiency virus-infected women who
receive highly active antiretroviral therapy.
 Haeri S, Shauer M, Dale M, et al
Am J Obstet Gynecol. 2009 Sep;201(3):315.e1-315.e5.
 Abstract

Improved Obstetric Outcomes and Few Maternal Toxicities Are Associated
With Antiretroviral Therapy, Including Highly Active Antiretroviral Therapy
During Pregnancy.
Tuomala RE, Watts DH, Li D, et all  
J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):449-473
 Abstract
     
   
ARVs and Vaginal Delivery
 
            Journal Papers, Abstracts, and Commentaries 
 
  The AmRo study: pregnancy outcome in HIV-1-infected women under effective highly
active antiretroviral therapy and a policy of vaginal delivery.
Boer K, Nellen JF, Patel D, et al 
BJOG. 2007 Feb;114(2):148-55.
Abstract
Adherence
 

            Journal Papers, Abstracts, and Commentaries 

 
Treatment Response in Association with Adherence Patterns to Highly Active Antiretroviral Therapy in Pediatric Patients with Perinatally Acquired HIV Infection.
Malhotra A, Whitley-Williams PN, et al
J Int Assoc Provid AIDS Care. 2014 Mar 17.
 Abstract

Factors affecting adherence to short-course ARV prophylaxis for preventing mother-to-child transmission of HIV in sub-Saharan Africa: a review and lessons for future elimination.
Colombini M, Stöckl H, Watts C,  et al  
AIDS Care. 2013 Dec 20.
 Abstract

Adherence to Antiretrovirals Among US Women During and After Pregnancy.
 Bardeguez AD, Lindsey JC, Shannon M, et al 
J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):408-417.
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Adherence to antiretroviral treatment among pregnant and postpartum HIV-infected women.
Mellins CA, Chu C, Malee K, et al
AIDS Care. 2008 Jun 17:1-11.
 Abstract
 
Adherence to Antiretrovirals Among US Women During and After Pregnancy.
 Bardeguez AD, Lindsey JC, Shannon M 
J Acquir Immune Defic Syndr. 2008 Jul 8.
 Abstract
 
Prior illicit drug use and missed prenatal vitamins predict nonadherence to antiretroviral
therapy in pregnancy: adherence analysis a5084.
Cohn SE, Umbleja T, Mrus J, et al 
AIDS Patient Care STDS. 2008 Jan;22(1):29-40.
 Abstract
Treatment Interruption
 

            Journal Papers, Abstracts, and Commentaries 

 
Pregnancy and treatment interruption enhances progression of HIV-infection if initial CD4(+) T-lymphocyte count is less than 700 cells/mm(3).
Orlova-Morozova E, Pronin A, Kaminskiy G.
 J Int AIDS Soc. 2012 Nov 11;15(6):
 Abstract
 
Treatment interruption after delivery in HIV-infected women without HAART indications is not safe if initial CD4(+) count is less than 700 cells/mm(3).
Kaminskiy G, Orlova-Morozova E, Pronin A.
 J Int AIDS Soc. 2012 Nov 11;15(6):
 Abstract

FULL-TEXT ARTICLE
Maternal CD4+ Cell Count Decline after Interruption of Antiretroviral Prophylaxis for the Prevention
of Mother-to-Child Transmission of HIV.
 Ekouevi D, Abrams EJ, Schlesinger M,  et al
PLoS One. 2012;7(8):e43750.
 Paper

A WEEK-IN-REVIEW FEATURED REPORT
Treatment interruption after pregnancy: effects on disease progression and laboratory findings.
 Watts DH, Lu M, Thompson B, et al  
 Infect Dis Obstet Gynecol. 2009;2009:456717
 Abstract

Is the Interruption of Antiretroviral Treatment During Pregnancy an Additional Major Risk
Factor for Mother-to-Child
Transmission of HIV Type 1?
 Galli L, Puliti D, Chiappini E, Gabiano C, et al 
Clin Infect Dis. 2009 Mar 23
 Abstract
Discontinuation of ARVs
 
            Journal Papers, Abstracts, and Commentaries 
 
  FULL-TEXT ARTICLE
 Postpartum Discontinuation of Antiretroviral Therapy and Risk of Maternal
AIDS-Defining Events, Non-AIDS-Defining Events, and Mortality Among
a Cohort of HIV-1-Infected Women in the United States.
 Melekhin VV, Shepherd BE, Jenkins CA, et al
AIDS Patient Care STDS. 2010 May 3.
 Paper

          Conference Reports, Abstracts, and Posters

 

Immunological dynamics after delivery in HIV-infected pregnant
women who discontinued combined antiretroviral use
R Palacios, J F Senise, Z N Tanno, et al
(15IAC)
 Abstract
Protease Inhibitors
 

          Journal Papers, Abstracts, and Commentaries

 
HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels;
a potential mechanism contributing to fetal growth restriction.
Papp E, Mohammadi H, Loutfy MR,et al
J Infect Dis. 2014 Jul 16
 Abstract

FULL-TEXT ARTICLE
Safety of protease inhibitors in HIV-infected pregnant women.
 Chougrani I, Luton D, Matheron S,
HIV AIDS (Auckl). 2013 Sep 27;5:253-262.
 Paper

HIV Protease Inhibitors in Pregnancy : Pharmacology and Clinical Use.
 Andany N, Loutfy MR.
Drugs. 2013 Feb 13.
Abstract

Premature Delivery in HIV-Infected Women Starting Protease Inhibitor Therapy During Pregnancy:
Role of the Ritonavir Boost?
 Sibiude J, Warszawski J, Tubiana R,  et al
Clin Infect Dis. 2012 May;54(9):1348-60
 Abstract

Combination antiretroviral therapy with protease inhibitors in HIV-infected pregnancy.
Dola CP, Khan R, Denicola N, et al
J Perinat Med. 2011 Nov 2.
 Abstract

Previous antiretroviral therapy for prevention of mother-to-child transmission of HIV does not hamper the initial response to PI-based multitherapy during subsequent pregnancy.
 Briand N, Mandelbrot L, Blanche S, Tubiana R, et al
J Acquir Immune Defic Syndr. 2011 Mar 23
 Abstract

Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women
initiating antiretroviral drugs during pregnancy.
 Patel K, Shapiro DE, Brogly SB,  et al 
J Infect Dis. 2010 Apr 1;201(7):1035-44.
 Abstract

Clinical pharmacology of HIV protease inhibitors in pregnancy.
van der Lugt J, Colbers A, Burger D.
 Curr Opin HIV AIDS. 2008 Nov;3(6):620-626
 Abstract

Protease Inhibitor Therapy and Fetal Growth Potential in HIV-Positive Women.
 Iqbal S, Kriebs J, Harman C, et al 
Am J Perinatol. 2008 May 28.
 Abstract

Lipids and Lactate in Human Immunodeficiency Virus-1 Infected Pregnancies With
or Without Protease Inhibitor-Based Therapy.
 Livingston EG, Cohn SE, Yang Y, et al
Obstet Gynecol. 2007 Aug;110(2):391-397.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS
Clinical Trials Group A5084.
Hitti J, Andersen J, McComsey G, et al  
Am J Obstet Gynecol. 2007 Apr;196(4):331.e1-7.
 Abstract
 
Protease Inhibitor Use in 233 Pregnancies.
 Morris AB, Dobles AR, Cu-Uvin S, 
J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):30-33.
 Abstract
 
The impact of protease inhibitors on maternal serum screening analyte levels
in pregnant women who are HIV positive.
Einstein FH, Wright RL, Trentacoste S, et al
Am J Obstet Gynecol. 2004 Sep;191(3):1004-8.
 Abstract

Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in
pregnant women who are infected with human immunodeficiency virus.
Chappuy H, Treluyer JM, Rey E, et  al
Am J Obstet Gynecol. 2004 Aug;191(2):558-62.
 Abstract
 
Insulin resistance complicating pregnancy in a human immunodeficiency virus-
infected patient treated with protease inhibitors and corticosteroids.
Aschkenazi S, Rochelson B, Bernasko J, Kaplan J.
Obstet Gynecol. 2003 Nov;102(5 Suppl):1210-2.
Abstract

Concentrations of protease inhibitors in cord blood after in utero exposure.
Mirochnick M, Dorenbaum A, Holland D,  
Pediatr Infect Dis J 2002 Sep;21(9):835-8
 Abstract
 
Protease Inhibitors and Decreased Birth Weight in HIV-Infected Pregnant Women
With Impaired Glucose Tolerance
 Chmait R, Franklin P, Spector SA, et al .
J Perinatol 2002 Jul-Aug;22(5):370-3
 Abstract
 
Transplacental passage of protease inhibitors at delivery.
 Marzolini C, Rudin C, Decosterd LA, et al.
 AIDS. 2002 Apr 12;16(6):889-893.
 Abstract
 

 
Nucleoside Analogues
 

          Journal Papers, Abstracts, and Commentaries

 
Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue
reverse transcriptase inhibitors in human immunodeficiency virus-infected
pregnant women.
Chappuy H, Treluyer JM, Jullien V, et al   
Antimicrob Agents Chemother. 2004 Nov;48(11):4332-6.
 Abstract

Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog
 drugs.
Poirier MC, Olivero OA, Walker DM, Walker VE. 
Toxicol Appl Pharmacol. 2004 Sep 1;199(2):151-61
 Abstract

Risk of early febrile seizure with perinatal exposure to nucleoside analogues.
Landreau-Mascaro A, Barret B, et al.
 Lancet 2002 Feb 16;359(9306):583-4
 Abstract

  
NNRTIs
 

          Journal Papers, Abstracts, and Commentaries

 
FULL-TEXT ARTICLE
 Effectiveness of Non-nucleoside Reverse-Transcriptase Inhibitor-Based Antiretroviral
Therapy in Women Previously Exposed to a Single Intrapartum Dose of Nevirapine:
A Multi-country, Prospective Cohort Study.
Stringer JS, McConnell MS, Kiarie J,  et al
PLoS Med. 2010 Feb 16;7(2):e1000233.
 Paper

Brief Report: Nonnucleoside Reverse Transcriptase Inhibitor Resistance Among
Antiretroviral-Naive HIV-Positive Pregnant Women.
Juethner SN, Williamson C, Ristig MB, et al.
J Acquir Immune Defic Syndr 2003 Feb 1;32(2):153-6
 Abstract

  
Treatment of Neonates
 
          Journal Papers, Abstracts, and Commentaries
 
  Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine,
nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected
children: week 24 results of a randomized controlled trial--PACTG 377.
Pediatric AIDS Clinical Trials Group 377 Study Team.
Wiznia A, Stanley K, Krogstad P, et al.
AIDS Res Hum Retroviruses 2000 Aug 10;16(12):1113-21
Abstract
 

HIV Pregnancy Main Page Women Main Page  

Pregnancy: General ARV Studies